Table of Content

1 INTRODUCTION (Page No. - 25)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
           1.2.1 INCLUSIONS AND EXCLUSIONS
           1.2.2 MARKETS COVERED
                    FIGURE 1 CLINICAL TRIAL IMAGING MARKET SEGMENTATION
           1.2.3 GEOGRAPHIC SCOPE
           1.2.4 YEARS CONSIDERED
           1.2.5 CURRENCY CONSIDERED
    1.3 LIMITATIONS 
    1.4 STAKEHOLDERS 
    1.5 SUMMARY OF CHANGES 
           1.5.1 RECESSION IMPACT
2 RESEARCH METHODOLOGY (Page No. - 30)
    2.1 RESEARCH DATA 
    2.2 RESEARCH APPROACH 
          FIGURE 2 MARKET: RESEARCH DESIGN
           2.2.1 SECONDARY DATA
                    2.2.1.1 Key data from secondary sources
           2.2.2 PRIMARY DATA
                    FIGURE 3 BREAKDOWN OF INTERVIEWS: SUPPLY AND DEMAND SIDE
                    2.2.2.1 Key data from primary sources
                    2.2.2.2 Key industry insights
                    2.2.2.3 Breakdown of primary interviews
                                FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY AND DEMAND-SIDE PARTICIPANTS
                                FIGURE 5 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
    2.3 MARKET SIZE ESTIMATION 
           2.3.1 BOTTOM-UP APPROACH
                    2.3.1.1 Approach 1: Company revenue estimation approach
                                FIGURE 6 BOTTOM-UP APPROACH: COMPANY REVENUE ESTIMATION APPROACH
                    2.3.1.2 Approach 2: Presentations of companies and primary interviews
                    2.3.1.3 Growth forecast
                    2.3.1.4 CAGR projections
                                FIGURE 7 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
           2.3.2 TOP-DOWN APPROACH
                    FIGURE 8 MARKET: TOP-DOWN APPROACH
    2.4 MARKET BREAKDOWN & DATA TRIANGULATION 
          FIGURE 9 DATA TRIANGULATION METHODOLOGY
    2.5 STUDY ASSUMPTIONS 
    2.6 RISK ASSESSMENT 
    2.7 LIMITATIONS 
    2.8 MARKET: RECESSION IMPACT 
3 EXECUTIVE SUMMARY (Page No. - 43)
    FIGURE 10 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 MARKET, BY MODALITY, 2023 VS. 2028 (USD MILLION)
    FIGURE 12 MARKET, BY THERAPEUTIC AREA, 2023 VS. 2028 (USD MILLION)
    FIGURE 13 MARKET, BY END USER, 2023 VS. 2028 (USD MILLION)
    FIGURE 14 MARKET, BY REGION, 2023 VS. 2028 (USD MILLION)
4 PREMIUM INSIGHTS (Page No. - 48)
    4.1 MARKET OVERVIEW 
          FIGURE 15 RISING R&D SPENDING TO DRIVE MARKET GROWTH
    4.2 MARKET SHARE, BY SERVICE & SOFTWARE, 2022 VS. 2028 
          FIGURE 16 SERVICES TO HOLD LARGEST MARKET SHARE TILL 2028
    4.3 MARKET SHARE, BY MODALITY, 2023 VS. 2028 
          FIGURE 17 COMPUTED TOMOGRAPHY TO COMMAND LARGEST SHARE OVER FORECAST PERIOD
    4.4 MARKET SHARE, BY THERAPEUTIC AREA, 2023 VS. 2028 
          FIGURE 18 ONCOLOGY TO DOMINATE MARKET, BY THERAPEUTIC AREA, TILL 2028
    4.5 MARKET SHARE, BY END USER, 2023 VS. 2028 
          FIGURE 19 PHARMACEUTICAL COMPANIES TO RETAIN MARKET LEADERSHIP OVER FORECAST PERIOD
    4.6 MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 
          FIGURE 20 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE TILL 2028
5 MARKET OVERVIEW (Page No. - 51)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 21 CLINICAL TRIAL IMAGING MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.2.1 DRIVERS
                    5.2.1.1 Increasing R&D spending
                    5.2.1.2 Growth of pharmaceutical and biotechnology industries
                    5.2.1.3 Increasing number of CROs
           5.2.2 RESTRAINTS
                    5.2.2.1 High implementation cost of imaging systems
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Growth opportunities in emerging economies
                    5.2.3.2 Development of innovative imaging modalities, contrast agents, molecular probes, and radiopharmaceuticals
           5.2.4 CHALLENGES
                    5.2.4.1 High cost of clinical trials
    5.3 PRICING ANALYSIS 
          TABLE 1 PRICES OF CLINICAL TRIAL IMAGING PRODUCTS (2022)
    5.4 PATENT ANALYSIS 
    5.5 TRADE ANALYSIS 
           5.5.1 TRADE ANALYSIS FOR X-RAY APPARATUSES
                    TABLE 2 IMPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
                    TABLE 3 EXPORT DATA FOR X-RAY APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
           5.5.2 TRADE ANALYSIS FOR CT APPARATUSES
                    TABLE 4 IMPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
                    TABLE 5 EXPORT DATA FOR CT APPARATUSES, BY COUNTRY, 2018–2022 (USD MILLION)
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 22 MARKET: VALUE CHAIN ANALYSIS
    5.7 SUPPLY CHAIN ANALYSIS 
          FIGURE 23 MARKET: SUPPLY CHAIN ANALYSIS
    5.8 ECOSYSTEM ANALYSIS 
          FIGURE 24 MARKET: ECOSYSTEM ANALYSIS
          TABLE 6 COMPANY ROLE IN ECOSYSTEM
    5.9 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 7 MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.9.1 THREAT OF NEW ENTRANTS
           5.9.2 THREAT OF SUBSTITUTES
           5.9.3 BARGAINING POWER OF BUYERS
           5.9.4 BARGAINING POWER OF SUPPLIERS
           5.9.5 DEGREE OF COMPETITION
    5.10 PESTLE ANALYSIS 
    5.11 REGULATORY LANDSCAPE 
           5.11.1 NORTH AMERICA
                    5.11.1.1 US
                    5.11.1.2 CANADA
           5.11.2 EUROPE
           5.11.3 ASIA PACIFIC
                    5.11.3.1 Japan
                    5.11.3.2 India
                    5.11.3.3 China
           5.11.4 LATIN AMERICA
                    5.11.4.1 Brazil
                    5.11.4.2 Mexico
           5.11.5 MIDDLE EAST
           5.11.6 AFRICA
    5.12 TECHNOLOGY ANALYSIS 
    5.13 CLINICAL TRIAL IMAGING: DISRUPTIVE TECHNOLOGIES 
           FIGURE 25 REVENUE SHIFT IN MARKET
6 CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE (Page No. - 67)
    6.1 INTRODUCTION 
          TABLE 8 MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
    6.2 SERVICES 
          TABLE 9 CLINICAL TRIAL IMAGING SERVICES MARKET, BY TYPE, 2021–2028 (USD MILLION)
          TABLE 10 CLINICAL TRIAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.1 OPERATIONAL IMAGING SERVICES
                    6.2.1.1 Rising number of CROs to drive market
                                TABLE 11 OPERATIONAL IMAGING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.2 READ ANALYSIS SERVICES
                    6.2.2.1 Growing clinical trial activity to support growth
                                TABLE 12 READ ANALYSIS SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.3 SYSTEM & TECHNICAL SUPPORT SERVICES
                    6.2.3.1 Need for continuous technical support to drive market
                                TABLE 13 SYSTEM & TECHNICAL SUPPORT SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
           6.2.4 TRIAL DESIGN & CONSULTING SERVICES
                    6.2.4.1 Rising R&D spending and need for clinical trial support to boost outsourcing
                                TABLE 14 TRIAL DESIGN & CONSULTING SERVICES MARKET, BY REGION, 2021–2028 (USD MILLION)
    6.3 SOFTWARE 
           6.3.1 HIGH EFFICIENCY AND COST-SAVING BENEFITS OF SOFTWARE TO BOOST ADOPTION
                    TABLE 15 CLINICAL TRIAL IMAGING SOFTWARE MARKET, BY REGION, 2021–2028 (USD MILLION)
7 CLINICAL TRIAL IMAGING MARKET, BY MODALITY (Page No. - 73)
    7.1 INTRODUCTION 
          TABLE 16 MARKET, BY MODALITY, 2021–2028 (USD MILLION)
    7.2 CT 
           7.2.1 QUICK RESULTS AND LACK OF VISIBLE SIDE EFFECTS TO DRIVE ADOPTION
                    TABLE 17 MARKET FOR CT, BY REGION, 2021–2028
    7.3 MRI 
           7.3.1 INCREASING ADOPTION OF MRI IN ONCOLOGICAL TRIALS AND STUDIES TO DRIVE MARKET
                    TABLE 18 MARKET FOR MRI, BY REGION, 2021–2028 (USD MILLION)
    7.4 ULTRASOUND 
           7.4.1 HIGH SAFETY TO ENSURE CONTINUED DEMAND
                    TABLE 19 MARKET FOR ULTRASOUND, BY REGION, 2021–2028 (USD MILLION)
    7.5 PET 
           7.5.1 ABILITY TO ASSESS PHARMACOKINETIC AND PHARMACODYNAMIC EVENTS TO BOOST ADOPTION
                    TABLE 20 MARKET FOR PET, BY REGION, 2021–2028 (USD MILLION)
    7.6 X-RAY 
           7.6.1 WIDE USAGE IN BONE, CHEST, AND DENTAL IMAGING TO DRIVE MARKET
                    TABLE 21 MARKET FOR X-RAY, BY REGION, 2021–2028 (USD MILLION)
    7.7 ECHOCARDIOGRAPHY 
           7.7.1 ADVANTAGES IN DEFINING AND QUALIFYING POPULATIONS TO BOOST USAGE
                    TABLE 22 MARKET FOR ECHOCARDIOGRAPHY, BY REGION, 2021–2028 (USD MILLION)
    7.8 OTHER MODALITIES 
          TABLE 23 MARKET FOR OTHER MODALITIES, BY REGION, 2021–2028 (USD MILLION)
8 CLINICAL TRIAL IMAGING MARKET, BY THERAPEUTIC AREA (Page No. - 81)
    8.1 INTRODUCTION 
          TABLE 24 MARKET, BY THERAPEUTIC AREA, 2021–2028 (USD MILLION)
    8.2 ONCOLOGY 
           8.2.1 INCREASING INCIDENCE OF CANCER TO DRIVE MARKET
                    TABLE 25 MARKET FOR ONCOLOGY, BY REGION, 2021–2028 (USD MILLION)
    8.3 INFECTIOUS DISEASES 
           8.3.1 RISING DRUG DISCOVERY ACTIVITY TO BOOST DEMAND FOR IMAGING
                    TABLE 26 MARKET FOR INFECTIOUS DISEASES, BY REGION, 2021–2028 (USD MILLION)
    8.4 NEUROLOGY 
           8.4.1 GROWING INVESTMENTS IN CNS DISORDER RESEARCH TO DRIVE MARKET
                    TABLE 27 MARKET FOR NEUROLOGY, BY REGION, 2021–2028 (USD MILLION)
    8.5 CVS DISORDERS 
           8.5.1 HIGH MORTALITY RATE OF CVD TO INCREASE CLINICAL TRIAL ACTIVITY
                    TABLE 28 MARKET FOR CVS DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    8.6 ENDOCRINOLOGY 
           8.6.1 RISING INCIDENCE OF DIABETES TO DRIVE MARKET
                    TABLE 29 MARKET FOR ENDOCRINOLOGY, BY REGION, 2021–2028 (USD MILLION)
    8.7 IMMUNOLOGICAL DISORDERS 
           8.7.1 WIDE PREVALENCE OF ALLERGIES, ASTHMA, AND AUTOIMMUNE DISEASES TO SUPPORT DEMAND FOR IMAGING IN TRIALS
                    TABLE 30 MARKET FOR IMMUNOLOGICAL DISORDERS, BY REGION, 2021–2028 (USD MILLION)
    8.8 OTHER THERAPEUTIC AREAS 
          TABLE 31 MARKET FOR OTHER THERAPEUTIC AREAS, BY REGION, 2021–2028 (USD MILLION)
9 CLINICAL TRIAL IMAGING MARKET, BY END USER (Page No. - 89)
    9.1 INTRODUCTION 
          TABLE 32 MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL COMPANIES 
           9.2.1 PHARMA COMPANIES TO HOLD LARGEST SHARE OF END-USER MARKET
                    FIGURE 26 RISING R&D INVESTMENTS IN PHARMACEUTICAL INDUSTRY, 2012–2026 (USD BILLION)
                    TABLE 33 MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2021–2028 (USD MILLION)
    9.3 BIOTECHNOLOGY COMPANIES 
           9.3.1 RISING R&D BUDGETS OF BIOTECH COMPANIES TO DRIVE MARKET
                    TABLE 34 TOP BIOTECHNOLOGY INVESTMENT DEALS, 2020
                    TABLE 35 MARKET FOR BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION)
    9.4 MEDICAL DEVICE MANUFACTURERS 
           9.4.1 INCREASING R&D SPENDING BY MEDICAL DEVICES MANUFACTURERS TO SUPPORT GROWTH
                    TABLE 36 MARKET FOR MEDICAL DEVICE MANUFACTURERS, BY REGION, 2021–2028 (USD MILLION)
    9.5 CROS 
           9.5.1 INCREASING TREND OF OUTSOURCING TO DRIVE MARKET
                    TABLE 37 MARKET FOR CROS, BY REGION, 2021–2028 (USD MILLION)
    9.6 ACADEMIC & GOVERNMENT RESEARCH INSTITUTES 
           9.6.1 INCREASING RESEARCH ACTIVITY TO DRIVE MARKET
                    TABLE 38 MARKET FOR ACADEMIC & GOVERNMENT RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION)
    9.7 OTHER END USERS 
          TABLE 39 MARKET FOR OTHER END USERS, BY REGION, 2021–2028 (USD MILLION)
10 CLINICAL TRIAL IMAGING MARKET, BY REGION (Page No. - 97)
     10.1 INTRODUCTION 
             TABLE 40 MARKET, BY REGION, 2021–2028 (USD MILLION)
     10.2 NORTH AMERICA 
             FIGURE 27 NORTH AMERICA: MARKET SNAPSHOT
             10.2.1 NORTH AMERICA: RECESSION IMPACT
                       TABLE 41 NORTH AMERICA: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                       TABLE 42 NORTH AMERICA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 43 NORTH AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 44 NORTH AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.2 US
                        10.2.2.1 Rising biopharma investment to favor market growth
                                      TABLE 45 US: PRODUCT APPROVALS IN CLINICAL TRIAL IMAGING
                                      TABLE 46 US: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 47 US: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 48 US: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.2.3 CANADA
                        10.2.3.1 Rising per capita healthcare spending to drive market
                                      TABLE 49 CANADA: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 50 CANADA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 51 CANADA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.3 EUROPE 
             10.3.1 EUROPE: RECESSION IMPACT
                       TABLE 52 EUROPE: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                       TABLE 53 EUROPE: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 54 EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 55 EUROPE: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.2 GERMANY
                        10.3.2.1 Germany to dominate market in Europe
                                      TABLE 56 GERMANY: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 57 GERMANY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 58 GERMANY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.3 UK
                        10.3.3.1 Favorable government initiatives and growing R&D spending to drive market
                                      TABLE 59 UK: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 60 UK: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 61 UK: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.4 FRANCE
                        10.3.4.1 Presence of leading pharmaceutical companies to support growth
                                      TABLE 62 FRANCE: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 63 FRANCE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 64 FRANCE: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.3.5 ITALY
                        10.3.5.1 Increasing drug approvals to ensure sustained demand for clinical trial imaging
                                      TABLE 65 ITALY: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 66 ITALY: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 67 ITALY: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.6 SPAIN
                        10.3.6.1 Increasing biologics production to support market growth
                                      TABLE 68 SPAIN: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 69 SPAIN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 70 SPAIN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.3.7 REST OF EUROPE
                       TABLE 71 REST OF EUROPE: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 72 REST OF EUROPE: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 73 REST OF EUROPE: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
     10.4 ASIA PACIFIC 
             FIGURE 28 ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET SNAPSHOT
             10.4.1 ASIA PACIFIC: RECESSION IMPACT
                       TABLE 74 ASIA PACIFIC: MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                       TABLE 75 ASIA PACIFIC: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 76 ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 77 ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.2 CHINA
                        10.4.2.1 China to dominate APAC market throughout forecast period
                                      TABLE 78 CHINA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 79 CHINA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 80 CHINA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.4.3 JAPAN
                        10.4.3.1 Rising population and healthcare expenditure to favor market growth
                                      TABLE 81 JAPAN: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 82 JAPAN: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 83 JAPAN: MARKET, BY END USER, 2021–2028 (USD MILLION)
             10.4.4 INDIA
                        10.4.4.1 Rising R&D investment to boost adoption of clinical trial imaging
                                      TABLE 84 INDIA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                                      TABLE 85 INDIA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                                      TABLE 86 INDIA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
             10.4.5 REST OF ASIA PACIFIC
                       TABLE 87 REST OF ASIA PACIFIC: CLINICAL TRIAL IMAGING MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 88 REST OF ASIA PACIFIC: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 89 REST OF ASIA PACIFIC: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.5 LATIN AMERICA 
             10.5.1 LOW COST OF RESOURCES, TAX ADVANTAGES TO ATTRACT PLAYER INTEREST
             10.5.2 LATIN AMERICA: RECESSION IMPACT
                       TABLE 90 LATIN AMERICA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 91 LATIN AMERICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 92 LATIN AMERICA: MARKET, BY END USER, 2021–2028 (USD MILLION)
     10.6 MIDDLE EAST & AFRICA 
             10.6.1 RISING RESEARCH FUNDING AND PARTNERSHIPS TO DRIVE MARKET
             10.6.2 MIDDLE EAST & AFRICA: RECESSION IMPACT
                       TABLE 93 MIDDLE EAST & AFRICA: MARKET, BY SERVICE & SOFTWARE, 2021–2028 (USD MILLION)
                       TABLE 94 MIDDLE EAST & AFRICA: MARKET, BY MODALITY, 2021–2028 (USD MILLION)
                       TABLE 95 MIDDLE EAST & AFRICA: CLINICAL TRIAL IMAGING INDUSTRY, BY END USER, 2021–2028 (USD MILLION)
11 COMPETITIVE LANDSCAPE (Page No. - 131)
     11.1 OVERVIEW 
     11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN 
             11.2.1 RIGHT-TO-WIN APPROACHES ADOPTED BY PLAYERS
                        TABLE 96 CLINICAL TRIAL IMAGING MARKET: STRATEGIES ADOPTED BY KEY PLAYERS
     11.3 REVENUE SHARE ANALYSIS OF TOP MARKET PLAYERS 
             FIGURE 29 REVENUE SHARE ANALYSIS OF KEY PLAYERS (2022)
     11.4 MARKET SHARE ANALYSIS 
             FIGURE 30 MARKET SHARE ANALYSIS OF KEY PLAYERS (2022)
             TABLE 97 CLINICAL TRIAL IMAGING INDUSTRY: DEGREE OF COMPETITION
     11.5 COMPANY EVALUATION MATRIX (2022) 
             11.5.1 STARS
             11.5.2 EMERGING LEADERS
             11.5.3 PERVASIVE PLAYERS
             11.5.4 PARTICIPANTS
                        FIGURE 31 MARKET: COMPANY EVALUATION MATRIX, 2022
     11.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES (2022) 
             11.6.1 PROGRESSIVE COMPANIES
             11.6.2 STARTING BLOCKS
             11.6.3 RESPONSIVE COMPANIES
             11.6.4 DYNAMIC COMPANIES
                        FIGURE 32 CLINICAL TRIAL IMAGING INDUSTRY: COMPANY EVALUATION MATIRX FOR STARTUPS/SMES, 2022
     11.7 COMPETITIVE BENCHMARKING 
             FIGURE 33 PRODUCT AND GEOGRAPHIC FOOTPRINT ANALYSIS OF KEY PLAYERS
             TABLE 98 COMPANY PRODUCT FOOTPRINT
             TABLE 99 COMPANY GEOGRAPHICAL FOOTPRINT
     11.8 COMPETITIVE SCENARIO 
             11.8.1 PRODUCT LAUNCHES & APPROVALS
                       TABLE 100 KEY PRODUCT LAUNCHES & APPROVALS (2020–2023)
             11.8.2 DEALS
                       TABLE 101 KEY DEALS (2020–2023)
12 COMPANY PROFILES (Page No. - 141)
(Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)*
     12.1 KEY PLAYERS 
             12.1.1 ICON PLC.
                       TABLE 102 ICON PLC.: BUSINESS OVERVIEW
                       FIGURE 34 ICON PLC.: COMPANY SNAPSHOT (2022)
             12.1.2 BIOTELEMETRY (PHILIPS)
                       TABLE 103 BIOTELEMETRY: BUSINESS OVERVIEW
                       FIGURE 35 PHILIPS GROUP: COMPANY SNAPSHOT (2022)
             12.1.3 MEDPACE HOLDINGS INC.
                       TABLE 104 MEDPACE HOLDINGS INC.: BUSINESS OVERVIEW
                       FIGURE 36 MEDPACE HOLDINGS INC.: COMPANY SNAPSHOT (2022)
             12.1.4 BIOMEDICAL SYSTEMS CORPORATION (ERT CLINICAL)
                       TABLE 105 BIOMEDICAL SYSTEMS CORPORATION: BUSINESS OVERVIEW
             12.1.5 BIOCLINICA INC. (CLARIO)
                       TABLE 106 BIOCLINICA INC.: BUSINESS OVERVIEW
             12.1.6 IXICO PLC.
                       TABLE 107 IXICO PLC.: BUSINESS OVERVIEW
                       FIGURE 37 IXICO PLC.: COMPANY SNAPSHOT (2022)
             12.1.7 RESONANCE HEALTH ANALYSIS SERVICES (RESONANCE HEALTH)
                       TABLE 108 RESONANCE HEALTH LTD.: BUSINESS OVERVIEW
                       FIGURE 38 RESONANCE HEALTH LTD.: COMPANY SNAPSHOT (2022)
             12.1.8 RADIANT SAGE LLC
                       TABLE 109 RADIANT SAGE LLC: BUSINESS OVERVIEW
             12.1.9 INTRINSIC IMAGING (WCG CLINICAL)
                       TABLE 110 WCG CLINICAL: BUSINESS OVERVIEW
             12.1.10 CARDIOVASCULAR IMAGING TECHNOLOGIES
                       TABLE 111 CARDIOVASCULAR IMAGING TECHNOLOGIES: BUSINESS OVERVIEW
     12.2 OTHER PLAYERS 
             12.2.1 MEDICAL METRICS
             12.2.2 PRISM CLINICAL IMAGING
             12.2.3 BOSTON IMAGING CORE LAB
             12.2.4 ANAGRAM 4 CLINICAL TRIALS
             12.2.5 LYSCAUT MEDICAL IMAGING COMPANY
             12.2.6 CALYX GROUP
             12.2.7 BIOSPECTIVE
             12.2.8 PROSCAN IMAGING
             12.2.9 MICRON, INC.
             12.2.10 IMAGING ENDPOINTS LI LLC.
             12.2.11 PERSPECTUM
             12.2.12 PHARMTRACE KLINISCHE ENTWICKLUNG GMBH
             12.2.13 WORLDCARE CLINICAL
             12.2.14 MEDIAN TECHNOLOGIES
             12.2.15 INVICRO. LLC.
*Details on Business Overview, Products/Solutions/Services Offered, Recent Developments, MnM view (Key strengths/Right to win, Strategic choices made, Weakness/competitive threats)* might not be captured in case of unlisted companies.
13 APPENDIX (Page No. - 172)
     13.1 DISCUSSION GUIDE 
     13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     13.3 CUSTOMIZATION OPTIONS 
     13.4 RELATED REPORTS 
     13.5 AUTHOR DETAILS